In the relentless arms race between cancer and therapy, even the most precisely targeted drugs can eventually fail. For patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an exceedingly rare and aggressive form of acute leukemia, the arrival of tagraxofusp in 2018 was a watershed moment. It was the first therapy ever approved specifically for this disease, offering a lifeline where few options existed. Designed as a molecular homing missile, tagraxofusp fuses the cytokine interleukin-3 (IL-3) to a truncated diphtheria toxin. The IL-3 moiety guides the drug directly to CD123, a receptor that dots the surface of BPDCN cells at unusually high densities. Once internalized, the toxin requires a critical enzymatic snip to unleash its lethal payload—a step that depends on the cellular reductase TXNRD1. This enzyme cleaves a disulfide bond within the toxin, freeing it to shut down protein synthesis and trigger cell death. For many patients, the strategy works spectacularly, but for roughly 10 to 25 percent of newly diagnosed individuals, the drug never gains traction, and many who initially respond later relapse.
Now, a team at The University of Texas MD Anderson Cancer Center has pinpointed the molecular escape hatch that cancer cells use to evade tagraxofusp. In a study published in Leukemia, co-led by senior research scientist Hannah Beird and leukemia physician-scientist Naveen Pemmaraju, the researchers performed a deep molecular autopsy on samples from a landmark Phase 2 trial of tagraxofusp. Their findings unveil a two-layered resistance mechanism involving severe mutations in the TET2 gene and a corresponding plunge in TXNRD1 levels, effectively disarming the weapon before it can strike. The work not only explains a frustrating clinical phenomenon but also provides a roadmap for predicting and overcoming resistance.
The investigation hinged on single-cell RNA sequencing of nearly 100,000 tumor cells from patients before and after treatment. This granular view allowed the team to identify a distinct subpopulation, which they labeled “cluster 22,” that stubbornly persisted even as the drug wiped out the bulk of malignant cells. Across these resistant cells, the expression of the TXNRD1 gene was consistently and markedly suppressed. Without sufficient reductase activity, the diphtheria toxin fragment remains locked in an inactive conformation, unable to ribosylate elongation factor 2 and halt protein production. The cancer cells, in essence, had learned to jam the release switch.
Digging deeper into the genetics of these resistant cells, the researchers discovered that severe, biallelic loss-of-function mutations in TET2 were strikingly enriched. TET2 is a well-known tumor suppressor and an epigenetic eraser that demethylates DNA, thereby regulating gene expression. When TET2 is crippled by severe mutations, the epigenetic landscape shifts, and the researchers found that this shift appears to silence the TXNRD1 locus, locking the reductase gene in a repressed state. Patients with normal or only mildly altered TET2 genes were far more likely to respond to tagraxofusp, suggesting that the gene’s mutational status could serve as a potent prognostic biomarker before treatment even begins.
Functional experiments cemented the causal link. When the team experimentally blocked TXNRD1 in BPDCN cell lines and patient-derived xenografts, the cancer cells became dramatically more resistant to tagraxofusp, recapitulating the clinical observation. Conversely, when they combined tagraxofusp with the hypomethylating agent azacitidine—a drug that reverses aberrant DNA methylation—the silenced TXNRD1 was reawakened and the resistant cells were resensitized. This combination strategy effectively restored the missing enzymatic activity, allowing the toxin to activate and kill the cells once more. The finding hints that co-treatment with epigenetic modulators could preemptively forestall the emergence of resistance in high-risk patients identified by TET2 sequencing.
For clinicians, these insights translate into actionable strategies. Checking TET2 mutation status at diagnosis could soon become standard practice for BPDCN, guiding the decision of whether to use tagraxofusp alone or to consider upfront combination therapy. Moreover, monitoring TXNRD1 levels through liquid biopsies or bone marrow assessments during treatment could provide an early warning signal of impending resistance, allowing for a therapeutic pivot before a full-blown relapse occurs. The study’s authors emphasize that such molecularly informed, dynamic treatment adjustments represent a paradigm shift from the traditional one-size-fits-all approach in rare leukemias.
The broader implications extend beyond BPDCN. Many targeted protein toxins and antibody-drug conjugates rely on intracellular reductases for activation, and the TET2-TXNRD1 axis may be a recurring motif in resistance to these agents. Pemmaraju noted that studying rare and ultra-rare tumors often yields insights that reverberate across more common cancers, serving as a blueprint for novel techniques. The combination of single-cell genomics and pharmacological rescue demonstrated here provides a template for dissecting resistance mechanisms in other malignancies where similar escape phenomena occur. As the team continues to validate these findings in prospective clinical trials, the hope is that BPDCN, once a disease with a grim prognosis, can be met with a series of ever-smarter countermeasures that keep the cancer on the back foot.
Subject of Research: Mechanisms of resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Article Title: Molecular Escape Hatch: How a Rare Leukemia Disarms the First Approved Therapy
News Publication Date: July 7, 2026
Web References: https://www.nature.com/articles/s41375-026-03022-0
References: Beird, H., Pemmaraju, N. et al. Leukemia, 2026. DOI: 10.1038/s41375-026-03022-0
Image Credits: The University of Texas MD Anderson Cancer Center
Keywords: BPDCN, tagraxofusp, drug resistance, TET2 mutations, TXNRD1, single-cell sequencing, CD123, targeted therapy, acute leukemia, epigenetic silencing, biomarker, hypomethylating agents
